Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gause, A.
Right arrow Articles by Pfreundschuh, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gause, A.
Right arrow Articles by Pfreundschuh, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 2:579-583, 1991
© 1991 European Society for Medical Oncology

research-article

Original article: The clinical Significance of serum CD8 antigen levels in adult patients with Hodgkin's disease

A. Gause, K. Verpoort, V. Roschansky, A. Tschiersch, D. Hasenclever, R. Schmits, V. Diehl, O. Brosteanu and M. Pfreundschuh

Medizinische Klinik I, University of Saarland and Medizinische Klinik I, University of Cologne Fed. Rep. Germany

Correspondence to: Michael Pfreundschuh, M.D., Medizinische Klinik I, Universität des Saarlandes, D-6650 Homburg, Fed. Rep. Germany

Increased suppressor T-cell activity has been observed in patients with Hodgkin's disease. In order to evaluate the clinical significance of soluble CD8 antigen (sCD8), which is released from CD8+ suppressor/ cytotoxic T-lymphocytes, we determined sCD8 levels in the sera of 82 consecutive patients with newly diagnosed untreated Hodgkin's lymphoma who were entered into prospective trials of the German Hodgkin's Disease Study Group. sCD8 levels were significantly higher (p < 0.01) in stage IV (781 U/ml, n= 19) than in stages I-IIIB (443 U/ml; n =63). Patients with B-symptoms (n =36) had slightly higher levels (611 U/ml) than patients without (n 46) systemic symptoms (447 U/ml; p = 0.08). In 77 patients evaluable for response, the complete remission (CR) rate of patients with sCD8 < 750 U/ml was higher (54/60 or 90%) than that of patients with sCD8 > 750 U/ml 11/17 or 65%; p=0.01). The time to treatment failure was significantly longer in patients with sCD8 < 750 U/ml (p = 0.008), even among the group with stages 111B/IV only (p = 0.04). Our data suggest that the pretreat-ment levels of sCD8 in adult patients with Hodgkin's lymphoma have prognostic relevance, and that they should be determined especially in patients with advanced disease. Increased understanding of the role of sCD8 may shed light on the pathogenesis of Hodgkin's disease.

CD8, Hodgkin's disease, prognostic factors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.